OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Posted by on Dec 4th, 2024

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a report issued on Tuesday morning. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

NASDAQ:OPGN opened at $1.60 on Tuesday. The stock’s 50-day moving average is $1.75 and its 200-day moving average is $2.29. OpGen has a 1-year low of $1.40 and a 1-year high of $9.90.

OpGen Company Profile

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.